Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 18
Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review [Erratum]
Authors Waheed W , Newman E, Aboukhatwa M , Moin M, Tandan R
Received 1 August 2022
Accepted for publication 1 August 2022
Published 3 August 2022 Volume 2022:18 Pages 773—774
Waheed W, Newman E, Aboukhatwa M, Moin M, Tandan R. Ther Clin Risk Manag. 2022;18:699–719.
The authors have advised there is an error in Table 1 on page 712. The value “1200 mg” in the Neisseria meningitidis vaccination row for the Induction Phase, Week 4 column for Refractory gMG Adult (≥18 years of age) Dosing Schedule, should read “900 mg”.
This error was introduced by the Editorial staff during the publication process.
© 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.